Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $50.0K | $75.0K | $90.0K | $90.0K | $90.0K | $90.0K | — | — | — |
| Revenue growth | — | — | 50.0% | 20.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Operating income | -$7.45M | -$9.99M | -$13.8M | -$15.6M | -$17.7M | -$23.5M | -$33.3M | -$36.7M | -$42.0M | -$38.5M |
| Operating margin | — | -19972.6% | -18385.5% | -17331.5% | -19678.5% | -26146.5% | -37017.8% | — | — | — |
| Net income | -$8.30M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.4M | -$39.7M |
| Net margin | — | -20769.9% | -16715.5% | -17291.3% | -19497.9% | -25616.0% | -37378.5% | — | — | — |
| EPS (diluted) | -$2.29 | -$1.89 | -$1.17 | -$0.77 | -$0.45 | -$0.23 | -$0.23 | -$5.57 | -$5.97 | -$3.38 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.90M | -$7.97M | -$11.3M | -$12.4M | -$16.9M | -$24.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M |
| Capital expenditures | — | $2.13K | — | — | $1.83K | $6.94K | — | — | — | — |
| Free cash flow | — | -$7.97M | — | — | -$16.9M | -$24.3M | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $294K | $3.20M | $9.18M | $7.89M | $13.9M | $70.1M | $41.7M | $26.5M | $3.25M | $4.25M |
| Total assets | $22.0M | $24.4M | $31.1M | $36.7M | $43.8M | $142M | $114M | $104M | $117M | $131M |
| Total liabilities | — | — | — | $9.59M | $10.1M | $9.65M | $10.6M | $12.2M | $42.5M | $53.4M |
| Shareholders' equity | $16.8M | $21.9M | $30.6M | $27.2M | $33.7M | $132M | $103M | $90.8M | $70.1M | $67.6M |
| Retained earnings | -$17.3M | -$27.7M | -$40.3M | -$53.0M | -$70.6M | -$96.0M | -$130M | -$162M | -$201M | -$239M |
| Shares (wtd avg diluted) | 4.88M | 8.35M | 16.2M | 28.9M | 55.6M | 109M | 146M | 6.05M | 6.73M | 11.1M |
Every figure is extracted from Citius Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.